Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

NCT04891809 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Isatuximab-Irfc 20 MG/ML [Sarclisa]
DRUG: Lenalidomide
DRUG: Dexamethasone Oral

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]